Patients with hepatocellular carcinoma that die during the first year of liver transplantation have high blood sFasL concentrations

doi:10.12998/wjcc.v11.i8.1753

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1818)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-2) series.

Item

Count

PDF

WORD

HTML

923

Figures (1-2)

214

Tables (1-2)

224

Sum=1482

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

111

Download

225

Sum=336

Mar 16, 2023 (publication date) through May 5, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Clin Cases. Mar 16, 2023; 11(8): 1753-1760
Published online Mar 16, 2023. doi: 10.12998/wjcc.v11.i8.1753

Patients with hepatocellular carcinoma that die during the first year of liver transplantation have high blood sFasL concentrations

Leonardo Lorente, Sergio T Rodriguez, Pablo Sanz, Agustín F González-Rivero, Antonia Pérez-Cejas, Javier Padilla, Dácil Díaz, Antonio González, María M Martín, Alejandro Jiménez, Purificación Cerro, Julián Portero, Manuel A Barrera

Leonardo Lorente, Intensive Care Unit, Hospital Universitario de Canarias, La Laguna 38320, Spain

Sergio T Rodriguez, María M Martín, Intensive Care Unit, Hospital Universitario Nuestra Señora Candelaria, Santa Cruz Tenerife 38010, Spain

Pablo Sanz, Javier Padilla, Manuel A Barrera, Department of Surgery, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz Tenerife 38010, Spain

Agustín F González-Rivero, Antonia Pérez-Cejas, Department of Laboratory, Hospital Universitario de Canarias, La Laguna 38320, Spain

Dácil Díaz, Antonio González, Department of Digestive, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz Tenerife 38010, Spain

Alejandro Jiménez, Research Unit, Hospital Universitario de Canarias, La Laguna 38320, Spain

Purificación Cerro, Transplant Unit, Hospital Universitario Nuestra Señora Candelaria, Santa Cruz Tenerife 38010, Spain

Julián Portero, Department of Radiology, Hospital Universitario Nuestra Señora Candelaria, Santa Cruz Tenerife 38010, Spain

Author contributions: Lorente L was responsible of conceive, design and coordinate the study, made substantial contributions to acquisition of data, analysis and interpretation of data, and drafted the manuscript; Rodriguez ST, Sanz P, Padilla J, Díaz D, González A, Martín MM, Cerro P, Portero J and Barrera MA have made substantial contributions to acquisition of data and provided useful suggestions; González-Rivero AF and Pérez-Cejas A participated in blood determination levels; Jiménez A have made substantial contributions to analysis and interpretation of data; All authors read critically and approved the manuscript, and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Institutional review board statement: The Institutional Board of the Hospital Universitario Nuestra Señora de Candelaria (Santa Cruz de Tenerife, Spain) approved the study protocol.

Informed consent statement: The informed consent to participate in the study was signed by the patient or a family member.

Conflict-of-interest statement: There are no conflicts of interest to declare.

Data sharing statement: The datasets generated during the current study are available from the corresponding author on reasonable request.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Leonardo Lorente, MD, PhD, Attending Doctor, Medical Assistant, Intensive Care Unit, Hospital Universitario de Canarias, Ofra, La Laguna 38320, Spain. lorentemartin@msn.com

Received: December 13, 2022
Peer-review started: December 13, 2022
First decision: January 19, 2023
Revised: January 20, 2023
Accepted: February 21, 2023
Article in press: February 21, 2023
Published online: March 16, 2023

Core Tip

Core Tip: Fas ligand (FasL) is one of the main ligands that activate apoptosis via the extrinsic pathway. Elevated blood concentrations of soluble FasL (sFasL) have not been found in patients with acute liver transplant (LT) rejection; however, the sample sizes of those studies were small. We found in this retrospective study of 127 patients with hepatocellular carcinoma underwent to LT that patients that die during the first year of LT have higher blood sFasL concentrations previously to LT than those who that remain alive. The beneficial results of blockade of the Fas system in animal models could motivate its investigation in these patients.